PE20050189A1 - Composiciones que comprenden derivados de acido quinoloncarboxilico para administracion local - Google Patents

Composiciones que comprenden derivados de acido quinoloncarboxilico para administracion local

Info

Publication number
PE20050189A1
PE20050189A1 PE2004000145A PE2004000145A PE20050189A1 PE 20050189 A1 PE20050189 A1 PE 20050189A1 PE 2004000145 A PE2004000145 A PE 2004000145A PE 2004000145 A PE2004000145 A PE 2004000145A PE 20050189 A1 PE20050189 A1 PE 20050189A1
Authority
PE
Peru
Prior art keywords
local administration
quinoloncarboxyl
acid derivatives
compositions including
refers
Prior art date
Application number
PE2004000145A
Other languages
English (en)
Inventor
Rainer Endermann
Harald Labischinski
Uwe Petersen
Ben Newton
Christoph Ladel
Original Assignee
Bayer Healthcare Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32851853&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20050189(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from DE10305318A external-priority patent/DE10305318A1/de
Priority claimed from DE10305319A external-priority patent/DE10305319A1/de
Application filed by Bayer Healthcare Ag filed Critical Bayer Healthcare Ag
Publication of PE20050189A1 publication Critical patent/PE20050189A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Abstract

SE REFIERE A COMPOSICIONES QUE COMPRENDEN DERIVADOS DE ACIDO QUINOLONCARBOXILICO (CIPROFLOXACINO, ENROFLOXACINO) DE ADMINISTRACION LOCAL, PRESENTADAS EN LA FORMA DE BETAINA SOLIDA Y/O COMO SAL DE BETAINA SOLIDA ESCASAMENTE SOLUBLE , PREFERENTEMENTE COMO EMBONATOS (TAMBIEN CONOCIDOS COMO PAMOATOS). EL USO DE ESTOS COMPUESTOS PARA LA FABRICACION DE MEDICAMENTOS DE ADMINISTRACION LOCAL PARA EL TRATAMIENTO ENFERMEDADES BACTERIANAS DE LOS ORGANOS RESPIRATORIOS EN HOMBRES Y ANIMALES. TAMBIEN SE REFIERA A DISPOSITIVOS QUE SON APROPIADOS PARA LA ADMINISTACION INHALATORIA DEL PRINCIPIO ACTIVO SOLIDO Y CONTIENE PREPARADOS CON AL MENOS UNO DE LOS COMPUESTOS DEFINIDOS ANTERIORMENTE
PE2004000145A 2003-02-10 2004-02-09 Composiciones que comprenden derivados de acido quinoloncarboxilico para administracion local PE20050189A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10305318A DE10305318A1 (de) 2003-02-10 2003-02-10 Behandlung bakteriell verursachter Lungenkrankheiten
DE10305319A DE10305319A1 (de) 2003-02-10 2003-02-10 Behandlung bakteriell verursachter Lungenkrankheiten

Publications (1)

Publication Number Publication Date
PE20050189A1 true PE20050189A1 (es) 2005-05-22

Family

ID=32851853

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2004000145A PE20050189A1 (es) 2003-02-10 2004-02-09 Composiciones que comprenden derivados de acido quinoloncarboxilico para administracion local

Country Status (28)

Country Link
US (2) US8034817B2 (es)
EP (1) EP1594500B1 (es)
JP (2) JP4828405B2 (es)
KR (1) KR101173696B1 (es)
AR (1) AR043117A1 (es)
AT (1) ATE482706T1 (es)
AU (1) AU2004210399B2 (es)
BR (1) BRPI0407368A (es)
CA (1) CA2515262C (es)
CY (1) CY1110998T1 (es)
DE (1) DE502004011696D1 (es)
DK (1) DK1594500T3 (es)
EC (1) ECSP055959A (es)
HK (1) HK1089380A1 (es)
HR (1) HRP20050786B1 (es)
IL (1) IL170027A (es)
MA (1) MA27632A1 (es)
MX (1) MXPA05008407A (es)
MY (1) MY144714A (es)
NO (1) NO331524B1 (es)
NZ (1) NZ541681A (es)
PE (1) PE20050189A1 (es)
PT (1) PT1594500E (es)
RU (1) RU2373937C9 (es)
SI (1) SI1594500T1 (es)
TW (1) TWI347843B (es)
UY (1) UY28179A1 (es)
WO (1) WO2004069253A1 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ541681A (en) * 2003-02-10 2009-02-28 Bayer Healthcare Ag Treatment of bacterial diseases of the respiratory organs by locally applying ciprofloxacin and its salts
US7157455B2 (en) * 2003-02-10 2007-01-02 Hoffmann-La Roche Inc. 4-Aminopyrimidine-5-one derivatives
WO2006033713A2 (en) * 2004-08-09 2006-03-30 Chiron Corporation Methods for ciprofloxacin inhalation
CA2585859C (en) 2004-10-29 2012-03-06 President And Fellows Of Harvard College Particles for treatment of pulmonary infection
LT1901749T (lt) * 2005-05-18 2016-10-25 Raptor Pharmaceuticals Inc. Aerozoliniai fluorchinolinai ir jų naudojimas
US8524734B2 (en) 2005-05-18 2013-09-03 Mpex Pharmaceuticals, Inc. Aerosolized fluoroquinolones and uses thereof
EP2285345A1 (en) 2008-05-15 2011-02-23 Novartis AG Pulmonary delivery of a fluoroquinolone
JP2012505222A (ja) 2008-10-07 2012-03-01 エムペックス・ファーマシューティカルズ・インコーポレーテッド 肺炎症を低減するためのレボフロキサシンの吸入
JP2012505223A (ja) 2008-10-07 2012-03-01 エムペックス・ファーマシューティカルズ・インコーポレーテッド 薬物動態の改善のためのエアゾールフルオロキノロン配合物
WO2010048341A1 (en) 2008-10-22 2010-04-29 Inspire Pharmaceuticals, Inc. Method for treating cystic fibrosis
AU2010289326B2 (en) 2009-09-04 2015-09-24 Horizon Therapeutics U.S. Holding Llc Use of aerosolized levofloxacin for treating cystic fibrosis
US9393243B1 (en) 2015-07-14 2016-07-19 Nilesh Parikh Topical Ciprofloxacin compositions
WO2018074880A2 (ko) * 2016-10-20 2018-04-26 한국화학연구원 퀴놀린 4-온 유도체 또는 이의 약학적으로 허용 가능한 염을 유효성분으로 포함하는 폐렴의 예방 또는 치료용 약학적 조성물

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3033157A1 (de) 1980-09-03 1982-04-01 Bayer Ag, 5090 Leverkusen 7-amino-1-cyclopropyl-4-oxo-1,4-dihydro-naphthyridin-3-carbonsaeuren, verfahren zu ihrer herstellung sowie diese enthaltende antibakterielle mittel
US4670444B1 (en) * 1980-09-03 1999-02-09 Bayer Ag and-naphthyridine-3-carboxylic acids and antibacte7-amino-1-cyclopropyl-4-oxo-1,4-dihydro-quinoline-rial agents containing these compounds
DE3525335A1 (de) * 1985-07-16 1987-01-22 Bayer Ag Embonate von chinoloncarbonsaeuren und ihren derivaten
DE3906365A1 (de) 1988-07-15 1990-01-18 Bayer Ag 7-(1-pyrrolidinyl)-3-chinolon- und -naphthyridoncarbonsaeure-derivate, verfahren sowie substituierte (oxa)diazabicyclooctane und -nonane als zwischenprodukte zu ihrer herstellung, und sie enthaltende antibakterielle mittel und futterzusatzstoffe
FR2655545B1 (fr) * 1989-12-11 1994-06-10 Rhone Poulenc Sante Nouvelle application therapeutique des derives des fluoroquinolones.
EP0504112A3 (en) * 1991-03-14 1993-04-21 Ciba-Geigy Ag Pharmaceutical aerosol formulations
DE4200821A1 (de) * 1992-01-15 1993-07-22 Bayer Ag Geschmacksmaskierte pharmazeutische mittel
DE19633480A1 (de) * 1996-08-20 1998-02-26 Bayer Ag Oral applizierbare Formulierungen von Chinolon- und Naphthyridoncarbonsäuren
DE19812160C1 (de) * 1998-03-20 1999-07-08 Bayer Ag Formkörper aus wirkstoffhaltigen thermoplastischen Polyurethanen
AU5528299A (en) * 1998-09-15 2000-04-03 Naeja Pharmaceutical Inc. Combined therapy for treatment of inflammation using elastase inhibitor(s) and antibacterial agent(s)
DE60044070D1 (de) * 1999-10-29 2010-05-06 Novartis Ag Trockenpulverzusammensetzungen mit verbesserter Dispersität
DE19962470A1 (de) 1999-12-22 2001-07-12 Schulz Hans Herrmann Verwendung von Chemotherapeutika
DE10031043A1 (de) * 2000-06-26 2002-02-14 Bayer Ag Retardzubereitungen von Chinolonantibiotika und Verfahren zu ihrer Herstellung
EP1490027A4 (en) * 2002-03-05 2010-11-10 Transave Inc METHODS OF TRAPPING BIOACTIVE AGENT IN A LIPOSOME OR LIPID COMPLEX
WO2003090715A2 (en) * 2002-04-25 2003-11-06 Nektar Therapeutics Uk Ltd Particulate materials
NZ541681A (en) * 2003-02-10 2009-02-28 Bayer Healthcare Ag Treatment of bacterial diseases of the respiratory organs by locally applying ciprofloxacin and its salts

Also Published As

Publication number Publication date
MXPA05008407A (es) 2005-10-05
JP2011173929A (ja) 2011-09-08
UY28179A1 (es) 2004-09-30
RU2373937C9 (ru) 2010-07-27
DK1594500T3 (da) 2011-01-24
RU2373937C2 (ru) 2009-11-27
AU2004210399A1 (en) 2004-08-19
RU2005128132A (ru) 2006-02-10
SI1594500T1 (sl) 2011-02-28
CA2515262C (en) 2013-09-03
BRPI0407368A (pt) 2006-02-14
MA27632A1 (fr) 2005-11-01
CA2515262A1 (en) 2004-08-19
NO20054180D0 (no) 2005-09-08
WO2004069253A1 (de) 2004-08-19
US8034817B2 (en) 2011-10-11
TWI347843B (en) 2011-09-01
DE502004011696D1 (de) 2010-11-11
ECSP055959A (es) 2006-01-16
US20040254194A1 (en) 2004-12-16
IL170027A (en) 2012-02-29
EP1594500A1 (de) 2005-11-16
PT1594500E (pt) 2010-12-17
EP1594500B1 (de) 2010-09-29
HRP20050786A2 (en) 2006-10-31
NO20054180L (no) 2005-09-08
JP4828405B2 (ja) 2011-11-30
JP2006517210A (ja) 2006-07-20
US20120010215A1 (en) 2012-01-12
AU2004210399B2 (en) 2010-02-18
AR043117A1 (es) 2005-07-20
MY144714A (en) 2011-10-31
CY1110998T1 (el) 2015-06-11
KR20050098309A (ko) 2005-10-11
NZ541681A (en) 2009-02-28
HK1089380A1 (en) 2006-12-01
KR101173696B1 (ko) 2012-08-13
HRP20050786B1 (hr) 2015-01-02
TW200503716A (en) 2005-02-01
ATE482706T1 (de) 2010-10-15
NO331524B1 (no) 2012-01-23

Similar Documents

Publication Publication Date Title
CY1119490T1 (el) Παραγωγα πυραζολοπυρρολιδινης και η χρηση τους στην θεραπεια νοσηματων
PE20050189A1 (es) Composiciones que comprenden derivados de acido quinoloncarboxilico para administracion local
ECSP105253A (es) Derivados de 5-feniltiazol y uso como inhibidores de pi3 cinasa
HN1999000183A (es) Preparado farmaceuticos de moxifloxacina
BR112015029491A2 (pt) derivados de imidazopirrolidinona e seu uso no tratamento de doença
AR055669A1 (es) Derivados de 3h - imidazo[4, 5 -b]piridina como inhibidores selectivos de gsk3, metodos e internediarios para su preparacion, composiciones farmaceuticas que los contienen y su uso para la elaboracion de un medicamento para el tratamiento de enfermedades neurodegenerativas y mentales.
ECSP045140A (es) Formulaciones farmacéuticas derivadas del platino
CY1115719T1 (el) Νεοι φαρμακευτικοι συνδυασμοι για τη θεραπεια νοσων των αναπνευστικων οδων
BR112013013950A2 (pt) antagonista de lpa1 policíclico e usos dos mesmos
ECSP066383A (es) Derivados de 5-fenil-4-metil-tiazol-2-il-amina como inhibidores de enzimas de cinasa fosfatidilinositol 3 (pi3) para el tratamiento de enfermedades inflamatorias de las vías respiratorias
ECSP088974A (es) Derivados de imidazol pirimidina para el tratamiento de enfermedades relacionadas con la glicógeno sintasa quinasa (gsk3)
NO20075136L (no) Nye liposompreparater
EA200702387A1 (ru) Имидазохинолины в качестве ингибиторов липидкиназы
UY29633A1 (es) Derivados de oxindol
ECSP066663A (es) Composición farmacéutica de vinflunina para administración parenteral, proceso de preparación y su uso
CL2007002228A1 (es) Composicion farmaceutica topica que comprende 1-(2-metilpropil)-1h-imidazo[4,5-c]quinolin-4-amina; composiicon empacada; metodos para esterelizarlas; util para cicatrizar tejido donde la dermis se ha desgarrado.
ECSP066770A (es) Nuevos ésteres de quinuclidina cuaternizados
AR057148A1 (es) Combinaciones farmacologicas para el tratamiento de enfermedades de las vias respiratorias
AR057319A1 (es) Composicion para la administracion topica y metodo para evitar o tratar infeccion o infestacion endoparasitica y ectoparasitica en un animal de sangre caliente
GB0606805D0 (en) Organic compounds
AR058116A1 (es) Parche transdermico adecuado para administrar nicotina a un individuo y uso de nicotina en forma de una sal para fabricarlo
UY28702A1 (es) Derivados de quinazolina
ATE543492T1 (de) Behandlung von lungenkrebs
UY28366A1 (es) Compuestos químicos
WO2017091767A3 (en) Drug formulations for cancer treatment

Legal Events

Date Code Title Description
FC Refusal